Other OTC - Delayed Quote USD

Elekta AB (publ) (EKTAY)

7.63 -0.04 (-0.56%)
At close: May 17 at 3:40 PM EDT
Loading Chart for EKTAY
DELL
  • Previous Close 7.67
  • Open 7.60
  • Bid --
  • Ask --
  • Day's Range 7.60 - 7.63
  • 52 Week Range 6.52 - 8.62
  • Volume 1,318
  • Avg. Volume 9,374
  • Market Cap (intraday) 2.968B
  • Beta (5Y Monthly) 1.02
  • PE Ratio (TTM) 21.79
  • EPS (TTM) 0.35
  • Earnings Date Jun 5, 2024
  • Forward Dividend & Yield 0.23 (2.95%)
  • Ex-Dividend Date Feb 26, 2024
  • 1y Target Est --

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

elekta.com

4,584

Full Time Employees

April 30

Fiscal Year Ends

Recent News: EKTAY

Performance Overview: EKTAY

Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

EKTAY
4.90%
OMX Stockholm 30 Index
8.51%

1-Year Return

EKTAY
7.44%
OMX Stockholm 30 Index
16.36%

3-Year Return

EKTAY
37.96%
OMX Stockholm 30 Index
15.76%

5-Year Return

EKTAY
24.16%
OMX Stockholm 30 Index
61.09%

Compare To: EKTAY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: EKTAY

Valuation Measures

Annual
As of 5/17/2024
  • Market Cap

    2.93B

  • Enterprise Value

    3.38B

  • Trailing P/E

    21.67

  • Forward P/E

    16.31

  • PEG Ratio (5yr expected)

    0.64

  • Price/Sales (ttm)

    1.71

  • Price/Book (mrq)

    3.03

  • Enterprise Value/Revenue

    1.99

  • Enterprise Value/EBITDA

    11.57

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.86%

  • Return on Assets (ttm)

    5.12%

  • Return on Equity (ttm)

    14.44%

  • Revenue (ttm)

    18.22B

  • Net Income Avi to Common (ttm)

    1.43B

  • Diluted EPS (ttm)

    0.35

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.35B

  • Total Debt/Equity (mrq)

    69.66%

  • Levered Free Cash Flow (ttm)

    1.66B

Research Analysis: EKTAY

Company Insights: EKTAY

Research Reports: EKTAY

People Also Watch